Related Experiment Video
Updated: Aug 9, 2026
09:04
DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
Effect of piroxicam beta-cyclodextrin complex on experimental inflammation
C A Amado1, S F Taniguchi, L S Sudo
1Depto. de Farmácia e Farmacologia, Universidade de Maringá, Paraná, Brazil.
General Pharmacology
|July 1, 1995
Summary
Piroxicam beta-cyclodextrin showed similar anti-inflammatory effects to piroxicam alone but enhanced leukocyte reduction in certain models. Beta-cyclodextrin may improve piroxicam
Area of Science:
- Pharmacology
- Drug Delivery
- Inflammation Research
Background:
- Piroxicam is a nonsteroidal anti-inflammatory drug (NSAID).
- Beta-cyclodextrin is a cyclic oligosaccharide used to enhance drug properties.
- Improving NSAID efficacy and delivery is crucial for treating inflammatory conditions.
Purpose of the Study:
- To compare the anti-inflammatory effectiveness of piroxicam-beta-cyclodextrin inclusion complex versus free piroxicam.
- To evaluate the impact of beta-cyclodextrin complexation on piroxicam's action in various inflammatory models.
Main Methods:
- Utilized three distinct experimental inflammatory models in rats.
- Assessed anti-inflammatory effects on granuloma tissue formation and arthritis induced by complete Freund adjuvant.
- Measured leukocyte mobilization in carrageenan-induced pleurisy.
Main Results:
- The piroxicam-beta-cyclodextrin complex exhibited anti-inflammatory effects comparable to free piroxicam in granuloma and arthritis models.
- The inclusion complex demonstrated a more potent reduction in leukocyte mobilization during carrageenan-induced pleurisy compared to non-complexed piroxicam.
- Beta-cyclodextrin complexation did not diminish, and in some aspects, enhanced piroxicam's anti-inflammatory activity.
Conclusions:
- Beta-cyclodextrin is a valuable tool for enhancing the efficacy of piroxicam.
- Complexation with beta-cyclodextrin offers a promising strategy for optimizing piroxicam's therapeutic potential in inflammatory diseases.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...